GREY:ICOTF - Post by User
Post by
GarryJan1on Dec 02, 2018 11:05pm
115 Views
Post# 29052151
Il liked the news update a few days ago
Il liked the news update a few days ago where it states Potential Partners. Nice if we get one of the big Pharma buy in and carry the rest of the costs to developement, or an offer to buy us out.
- On July 30, 2018, an iCo licensee received a positive opinion from the European Medicines Agency in support of its' request for orphan designation for iCo-008 in the treatment of BP. This was followed on August 20, 2018, by Orphan Drug Designation for the use of iCo-008 in BP from the U.S. Food and Drug Administration.
- On September 11, 2018, an iCo licensee announced that the FDA had granted Fast Track designation to Bertilimumab for the treatment of BP.
- During the quarter, the Company's Australian subsidiary received its Australian tax credit of $462,000 AUD related to its research and development work in Australia.
- On August 14, 2018 iCo filed a short form base shelf prospectus (the "Base Shelf") with securities regulators in the provinces of British Columbia, Alberta and Ontario. The Base Shelf allows iCo to offer, from time to time in one or more public offerings, up to $25,000,000 of common shares, preferred shares, debt securities, subscription receipts, units or warrants, or any combination thereof, during the 25-month period ending September 14, 2020. iCo filed the Base Shelf to provide the Company with financing flexibility going forward.
- iCo also continued to discuss potential partnerships with respect to the two clinical staged assets.
https://www.stockhouse.com/news/press-releases/2018/11/29/ico-therapeutics-announces-third-quarter-2018-financial-results-and-corporate#H5zMJQxjX5VLwe4O.99